AI-Powered Drug Discovery Market Size, Share & Trends Analysis Report by Offering (Software Platforms, AI Algorithms and Models, Cloud-Based Drug Discovery Platforms, Data Analytics Platforms, Services), Technology, Drug Type, Discovery Stage, Therapeutic Area, Deployment Mode, Data Type, Application, End User and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035
|
Market Structure & Evolution |
|
|
Segmental Data Insights |
|
|
Demand Trends |
|
|
Competitive Landscape |
|
|
Strategic Development |
|
|
Future Outlook & Opportunities |
|
AI-Powered Drug Discovery Market Size, Share, and Growth
The global AI-powered drug discovery market is experiencing robust growth, with its estimated value of USD 1 billion in the year 2025 and USD 9.2 billion by 2035, registering a CAGR of 24.6% during the forecast period.
AI-based drug discovery platform which we have developed will enable researchers and biotech partners to speed up their work in discovering and developing promising drug candidates. The combination of Lilly's long-standing scientific knowledge and our advanced artificial intelligence and machine learning technologies will help us achieve faster drug development times and lower expenses while delivering new medicines to patients.
The AI‑powered drug discovery market is experiencing rapid expansion because machine learning and deep learning and in‑silico modeling technologies help researchers find targets and optimize compounds. Eli Lilly introduced TuneLab in September 2025 as an AI platform that provides biotech partners with advanced predictive models to decrease their development periods and expenses.
Additionally, Nabla Bio extended its AI drug design collaboration with Takeda Pharmaceutical in October 2025 to use AI for more efficient protein-based therapeutic design.
The increasing need for effective treatments in oncology and rare diseases and infectious diseases has led pharmaceutical companies to make substantial investments in artificial intelligence solutions. The combination of technological innovation and strategic partnerships and growing artificial intelligence implementation is enabling drug discovery to proceed at a faster pace while developing potential breakthrough medical treatments.
Moreover, companies are able to explore adjacent opportunities which include AI-based clinical trial design systems and computational toxicology platforms and generative chemistry engines and digital biomarkers. Companies that develop R&D productivity through these specific areas will achieve a dual benefit which includes expanding their service capacity and accelerating therapy delivery to patients that will drive ongoing market expansion.
AI-Powered Drug Discovery Market Dynamics and Trends
Driver: Increasing Industry Imperatives Accelerating AI‑Powered Drug Discovery Adoption
-
The AI-powered drug discovery market is growing because R&D expenses keep increasing and traditional pipelines fail too often and biomedical data keeps growing which makes machine learning models for target identification and molecule screening more valuable to pharmaceutical companies. AI analytics are able to decrease both development time and development expenses by more than 50% when compared to traditional approaches.
- The US Food and Drug Administration (FDA) is currently promoting AI-driven and hybrid testing methods which will decrease animal testing requirements while companies such as Certara and Recursion use AI to predict drug toxicity and safety which accelerates their preclinical testing process.
- Companies use AI to deepen their understanding of complex biological systems while growing chronic disease treatment demands and precision medicine needs drive them to advance their research work. All these factors are likely to continue to escalate the growth of the AI-powered drug discovery market.
Restraint: Data Quality, Regulatory Uncertainty and Integration Challenges
-
The AI-powered drug discovery market has seen tremendous growth; moreover, constraints on data quality and integration reduce the reliability of models (due to incomplete, siloed, or inconsistent data sets) and limit the utility of predictive tools (e.g., AI) for drug discovery.
- Current regulatory development for AI in drug discovery lacks clarity concerning the evaluation(s) of AI-generated results for safety and effectiveness. Lack of clarity, combined with a compliance risk, may impede progress toward developing a broad application of AI.
- The logistical challenge involved in integrating AI into established R&D workflows requires not only significant capital investment in technology infrastructure but also a multidisciplinary workforce to implement and maintain the implementation. This challenge likely inhibits smaller biotech companies and other conventional research entities from adopting (i.e. using) AI technologies to their full potential. All these elements are expected to restrict the expansion of the AI-powered drug discovery market.
Opportunity: Strategic Collaborations and Biotech Innovation Ecosystems
-
Partnerships between AI technology firms and major pharmaceutical players are creating new avenues for innovation and expansion. U.S. biotech company Nabla Bio extended its multi‑year AI drug design partnership with Takeda Pharmaceutical from Japan to use AI for developing protein-based therapies which will enable faster candidate delivery than traditional methods.
- The venture capital influx into AI biotech startups which includes Chai Discovery's USD 70 million funding to enhance AI-driven molecular design capabilities demonstrates investor trust and speeds up platform development which will solve previously unsolvable challenges.
- The current trend of organizations working together and making investments creates chances to develop specific AI services through cloud-based drug discovery platforms and inter-institutional data exchange networks which will enhance innovation while sharing operational risks. And thus, is expected to create more opportunities in future for AI-powered drug discovery market.
Key Trend: Integration of Advanced AI, Data Infrastructure, and Predictive Modeling
-
The main trend in current research work involves scientists combining high-performance computing systems with deep learning algorithms and large data repositories which create strong predictive models that enable scientists to conduct efficient molecular simulations during early discovery phases of their work.
- AI-powered tools such as knowledge graph databases for complex disease target analysis (e.g., at Alzheimer’s research institutes) are being deployed to prioritize targets faster, illustrating how technology improves biomedical insight workflows.
- The industry undergoes transformation through the establishment of strategic partnerships which combine artificial intelligence systems with specialized knowledge to create new methods for drug pipeline development, optimization, and testing, which results in more efficient and predictive discovery methods that use iterative processes. Therefore, is expected to influence significant trends in the AI-powered drug discovery market.
AI-Powered Drug Discovery Market Analysis and Segmental Data
Drug Repurposing Dominates Global AI-Powered Drug Discovery Market amid Rising R&D Costs and Demand for Faster Therapeutics
-
The AI-powered drug discovery market shows its strong dependence on drug repurposing because AI capabilities enable fast examination of existing compounds which leads to shorter development periods and decreased expenses when compared to new drug development processes.
- Additionally, AI models are capable of discovering hidden drug-disease relationships through their ability to process large electronic health record and real-world evidence datasets which helps in both candidate selection and regulatory processes.
- Researchers at Monash University developed an AI tool which they adapted from its original purpose of assessing buyer behavior to assess drug safety and repurposing potential. The method proves especially useful for treating rare diseases and chronic diseases which require lengthy and costly research through standard drug development processes marking drug repurposing as the leading segment in AI-powered drug discovery market.
North America Dominates AI‑Powered Drug Discovery Market amid Strong Digital Health Infrastructure and Biotech Investments
-
North America holds the top position in the AI‑powered drug discovery market because of its developed healthcare IT systems, its considerable investment in research and development, and its high number of pharmaceutical and AI technology companies which drive the adoption of AI technology throughout their drug discovery operations.
- For instance, the pharmaceutical industry in the United States demonstrates its dedication to technological research through its recent partnership between Eli Lilly and NVIDIA to develop an AI supercomputer which will enhance drug discovery processes and reduce development times.
- The region benefits from substantial venture capital funding, collaborative ecosystems linking biotech startups with major pharma, and supportive regulatory frameworks that encourage AI validation and use, which enables researchers to identify targets and design molecules at an accelerated pace. The combination of these elements enables North America to maintain its leadership position in AI-powered drug discovery market.
AI-Powered Drug Discovery Market Ecosystem
The AI-powered drug discovery market is moderately consolidated. The market contains three player tiers which start with Isomorphic Labs, Insilico Medicine, Recursion, NVIDIA, and Exscientia as Tier 1 companies and proceed to Tier 2 companies Atomwise and Deep Genomics and end with Tier 3 companies which consist of specialized AI startups.
The main value chain components of the process include AI-driven target detection artificial intelligence-based lead development and predictive model creation. The Bristol Myers Squibb–Takeda–AbbVie consortium used OpenFold3 to enhance their protein–small molecule interaction prediction capabilities which showcases their collaborative efforts and ecosystem development.
Recent Development and Strategic Overview:
-
In August 2025, Scipher Medicine launched ClinicalTrialRank.com, an AI‑powered platform which accurately forecasts clinical trial failures. Through this tool biopharmaceutical companies and investors can predict trial success rates during the early development phase which helps them make better investment choices while decreasing financial losses. The platform provides predictive insights to customers which improves their decision-making capabilities while streamlining their drug development processes.
- In September 2025, the major pharmaceutical companies partnered with Eli Lilly and Superluminal Medicines to establish a collaboration worth USD 1.3 billion which will use advanced AI technology for developing structure-based drug discovery systems that will accelerate the discovery process of small-molecule drugs targeting cardiometabolic diseases and obesity.
Report Scope
|
Attribute |
Detail |
|
Market Size in 2025 |
USD 1 Bn |
|
Market Forecast Value in 2035 |
USD 9.2 Bn |
|
Growth Rate (CAGR) |
24.6% |
|
Forecast Period |
2025 – 2035 |
|
Historical Data Available for |
2020 – 2024 |
|
Market Size Units |
USD Billion for Value |
|
Report Format |
Electronic (PDF) + Excel |
|
Regions and Countries Covered |
|||||
|
North America |
Europe |
Asia Pacific |
Middle East |
Africa |
South America |
|
|
|
|
|
|
|
Companies Covered |
|||||
|
|
|
|
|
|
AI-Powered Drug Discovery Market Segmentation and Highlights
|
Segment |
Sub-segment |
|
AI-Powered Drug Discovery Market, By Offering |
|
|
AI-Powered Drug Discovery Market, By Technology |
|
|
AI-Powered Drug Discovery Market, By Drug Type |
|
|
AI-Powered Drug Discovery Market, By Discovery Stage |
|
|
AI-Powered Drug Discovery Market, By Therapeutic Area |
|
|
AI-Powered Drug Discovery Market, By Deployment Mode |
|
|
AI-Powered Drug Discovery Market, By Data Type |
|
|
AI-Powered Drug Discovery Market, By Application |
|
|
AI-Powered Drug Discovery Market, By End User |
|
Frequently Asked Questions
Table of Contents
- 1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
- 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
- 1.6.1. Open Natures
- 1.6.2. Paid Databases
- 1.6.3. Associations
- 1.7. Primary Research
- 1.7.1. Primary Natures
- 1.7.2. Primary Interviews with Stakeholders across Ecosystem
- 2. Executive Summary
- 2.1. Global AI-Powered Drug Discovery Market Outlook
- 2.1.1. AI-Powered Drug Discovery Market Size (Value - US$ Bn), and Forecasts, 2021-2035
- 2.1.2. Compounded Annual Growth Rate Analysis
- 2.1.3. Growth Opportunity Analysis
- 2.1.4. Segmental Share Analysis
- 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
- 2.5.1. Customer/ End-use Industry Assessment
- 2.5.2. Growth Opportunity Data, 2026-2035
- 2.5.2.1. Regional Data
- 2.5.2.2. Country Data
- 2.5.2.3. Segmental Data
- 2.5.3. Identification of Potential Market Spaces
- 2.5.4. GAP Analysis
- 2.5.5. Potential Attractive Price Points
- 2.5.6. Prevailing Market Risks & Challenges
- 2.5.7. Preferred Sales & Marketing Strategies
- 2.5.8. Key Recommendations and Analysis
- 2.5.9. A Way Forward
- 2.1. Global AI-Powered Drug Discovery Market Outlook
- 3. Industry Data and Premium Insights
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
- 3.1.1. Healthcare & Pharmaceutical Industry Analysis
- 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
- 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
- 3.2. Supplier Customer Data
- 3.3. Technology Roadmap and Developments
- 3.4. Trade Analysis
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
- 4. Market Overview
- 4.1. Market Dynamics
- 4.1.1. Drivers
- 4.1.1.1. Growing adoption of decentralized and remote healthcare solutions.
- 4.1.1.2. Increased need for faster and cost-effective clinical trial processes.
- 4.1.1.3. Rising prevalence of chronic diseases boosting demand for patient-centric trials.
- 4.1.2. Restraints
- 4.1.2.1. Data privacy and cybersecurity concerns in handling patient information.
- 4.1.2.2. Limited technological infrastructure in emerging markets restricting adoption.
- 4.1.1. Drivers
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
- 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
- 4.3.2. Tariffs and Standards
- 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Value Chain Analysis
- 4.5. Cost Structure Analysis
- 4.6. Porter’s Five Forces Analysis
- 4.7. PESTEL Analysis
- 4.8. Global AI-Powered Drug Discovery Market Demand
- 4.8.1. Historical Market Size – Value (US$ Bn), 2020-2024
- 4.8.2. Current and Future Market Size – Value (US$ Bn), 2026–2035
- 4.8.2.1. Y-o-Y Growth Trends
- 4.8.2.2. Absolute $ Opportunity Assessment
- 4.1. Market Dynamics
- 5. Competition Landscape
- 5.1. Competition structure
- 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
- 5.2.1. Global Company Market Share
- 5.2.2. By Region
- 5.2.2.1. North America
- 5.2.2.2. Europe
- 5.2.2.3. Asia Pacific
- 5.2.2.4. Middle East
- 5.2.2.5. Africa
- 5.2.2.6. South America
- 5.3. Product Comparison Matrix
- 5.3.1. Specifications
- 5.3.2. Market Positioning
- 5.3.3. Pricing
- 5.1. Competition structure
- 6. Global AI-Powered Drug Discovery Market Analysis, by Offering
- 6.1. Key Segment Analysis
- 6.2. AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, by Offering, 2021-2035
- 6.2.1. Software Platforms
- 6.2.2. AI Algorithms and Models
- 6.2.3. Cloud-Based Drug Discovery Platforms
- 6.2.4. Data Analytics Platforms
- 6.2.5. Services
- 7. Global AI-Powered Drug Discovery Market Analysis, by Technological
- 7.1. Key Segment Analysis
- 7.2. AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, by Technological, 2021-2035
- 7.2.1. Machine Learning (ML)
- 7.2.2. Deep Learning
- 7.2.3. Natural Language Processing (NLP)
- 7.2.4. Computer Vision
- 7.2.5. Reinforcement Learning
- 7.2.6. Generative AI Models
- 7.2.7. Others
- 8. Global AI-Powered Drug Discovery Market Analysis, by Drug Type
- 8.1. Key Segment Analysis
- 8.2. AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, by Drug Type, 2021-2035
- 8.2.1. Small Molecules
- 8.2.2. Large Molecules / Biologics
- 8.2.3. Gene Therapy-Based Drugs
- 8.2.4. RNA-Based Therapeutics
- 8.2.5. Others
- 9. Global AI-Powered Drug Discovery Market Analysis, by Discovery Stage
- 9.1. Key Segment Analysis
- 9.2. AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, by Discovery Stage, 2021-2035
- 9.2.1. Target Identification and Validation
- 9.2.2. Hit Identification / Screening
- 9.2.3. Hit-to-Lead Optimization
- 9.2.4. Lead Optimization
- 9.2.5. Preclinical Testing
- 9.2.6. Others
- 10. Global AI-Powered Drug Discovery Market Analysis, by Therapeutic Area
- 10.1. Key Segment Analysis
- 10.2. AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, by Therapeutic Area, 2021-2035
- 10.2.1. Oncology
- 10.2.2. Neurology and Neurodegenerative Diseases
- 10.2.3. Cardiovascular Diseases
- 10.2.4. Infectious Diseases
- 10.2.5. Metabolic Disorders
- 10.2.6. Immunology and Autoimmune Diseases
- 10.2.7. Respiratory Disorders
- 10.2.8. Rare Diseases
- 10.2.9. Others
- 11. Global AI-Powered Drug Discovery Market Analysis, by Deployment Mode
- 11.1. Key Segment Analysis
- 11.2. AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, by Deployment Mode, 2021-2035
- 11.2.1. Cloud-Based Platforms
- 11.2.2. On-Premise Platforms
- 11.2.3. Hybrid Deployment
- 12. Global AI-Powered Drug Discovery Market Analysis, by Data Type
- 12.1. Key Segment Analysis
- 12.2. AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, by Data Type, 2021-2035
- 12.2.1. Genomics Data
- 12.2.2. Proteomics Data
- 12.2.3. Clinical Trial Data
- 12.2.4. Chemical Structure Data
- 12.2.5. Real-World Data (RWD)
- 12.2.6. Others
- 13. Global AI-Powered Drug Discovery Market Analysis, by Application
- 13.1. Key Segment Analysis
- 13.2. AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, by Application, 2021-2035
- 13.2.1. Target Identification
- 13.2.2. Drug Repurposing
- 13.2.3. De Novo Drug Design
- 13.2.4. Virtual Screening
- 13.2.5. Biomarker Discovery
- 13.2.6. Toxicity Prediction
- 13.2.7. Pharmacokinetics and ADMET Prediction
- 13.2.8. Others
- 14. Global AI-Powered Drug Discovery Market Analysis, by End User
- 14.1. Key Segment Analysis
- 14.2. AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, by End User, 2021-2035
- 14.2.1. Pharmaceutical Companies
- 14.2.2. Biotechnology Companies
- 14.2.3. Contract Research Organizations (CROs)
- 14.2.4. Academic and Research Institutes
- 14.2.5. Healthcare AI Startups
- 14.2.6. Others
- 15. Global AI-Powered Drug Discovery Market Analysis and Forecasts, by Region
- 15.1. Key Findings
- 15.2. AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
- 15.2.1. North America
- 15.2.2. Europe
- 15.2.3. Asia Pacific
- 15.2.4. Middle East
- 15.2.5. Africa
- 15.2.6. South America
- 16. North America AI-Powered Drug Discovery Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. North America AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 16.3.1. Offering
- 16.3.2. Technological
- 16.3.3. Drug Type
- 16.3.4. Discovery Stage
- 16.3.5. Therapeutic Area
- 16.3.6. Deployment Mode
- 16.3.7. Data Type
- 16.3.8. Application
- 16.3.9. End User
- 16.3.10. Country
- 16.3.10.1. USA
- 16.3.10.2. Canada
- 16.3.10.3. Mexico
- 16.4. USA AI-Powered Drug Discovery Market
- 16.4.1. Country Segmental Analysis
- 16.4.2. Offering
- 16.4.3. Technological
- 16.4.4. Drug Type
- 16.4.5. Discovery Stage
- 16.4.6. Therapeutic Area
- 16.4.7. Deployment Mode
- 16.4.8. Data Type
- 16.4.9. Application
- 16.4.10. End User
- 16.5. Canada AI-Powered Drug Discovery Market
- 16.5.1. Country Segmental Analysis
- 16.5.2. Offering
- 16.5.3. Technological
- 16.5.4. Drug Type
- 16.5.5. Discovery Stage
- 16.5.6. Therapeutic Area
- 16.5.7. Deployment Mode
- 16.5.8. Data Type
- 16.5.9. Application
- 16.5.10. End User
- 16.6. Mexico AI-Powered Drug Discovery Market
- 16.6.1. Country Segmental Analysis
- 16.6.2. Offering
- 16.6.3. Technological
- 16.6.4. Drug Type
- 16.6.5. Discovery Stage
- 16.6.6. Therapeutic Area
- 16.6.7. Deployment Mode
- 16.6.8. Data Type
- 16.6.9. Application
- 16.6.10. End User
- 17. Europe AI-Powered Drug Discovery Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Europe AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 17.3.1. Offering
- 17.3.2. Technological
- 17.3.3. Drug Type
- 17.3.4. Discovery Stage
- 17.3.5. Therapeutic Area
- 17.3.6. Deployment Mode
- 17.3.7. Data Type
- 17.3.8. Application
- 17.3.9. End User
- 17.3.10. Country
- 17.3.10.1. Germany
- 17.3.10.2. United Kingdom
- 17.3.10.3. France
- 17.3.10.4. Italy
- 17.3.10.5. Spain
- 17.3.10.6. Netherlands
- 17.3.10.7. Nordic Countries
- 17.3.10.8. Poland
- 17.3.10.9. Russia & CIS
- 17.3.10.10. Rest of Europe
- 17.4. Germany AI-Powered Drug Discovery Market
- 17.4.1. Country Segmental Analysis
- 17.4.2. Offering
- 17.4.3. Technological
- 17.4.4. Drug Type
- 17.4.5. Discovery Stage
- 17.4.6. Therapeutic Area
- 17.4.7. Deployment Mode
- 17.4.8. Data Type
- 17.4.9. Application
- 17.4.10. End User
- 17.5. United Kingdom AI-Powered Drug Discovery Market
- 17.5.1. Country Segmental Analysis
- 17.5.2. Offering
- 17.5.3. Technological
- 17.5.4. Drug Type
- 17.5.5. Discovery Stage
- 17.5.6. Therapeutic Area
- 17.5.7. Deployment Mode
- 17.5.8. Data Type
- 17.5.9. Application
- 17.5.10. End User
- 17.6. France AI-Powered Drug Discovery Market
- 17.6.1. Country Segmental Analysis
- 17.6.2. Offering
- 17.6.3. Technological
- 17.6.4. Drug Type
- 17.6.5. Discovery Stage
- 17.6.6. Therapeutic Area
- 17.6.7. Deployment Mode
- 17.6.8. Data Type
- 17.6.9. Application
- 17.6.10. End User
- 17.7. Italy AI-Powered Drug Discovery Market
- 17.7.1. Country Segmental Analysis
- 17.7.2. Offering
- 17.7.3. Technological
- 17.7.4. Drug Type
- 17.7.5. Discovery Stage
- 17.7.6. Therapeutic Area
- 17.7.7. Deployment Mode
- 17.7.8. Data Type
- 17.7.9. Application
- 17.7.10. End User
- 17.8. Spain AI-Powered Drug Discovery Market
- 17.8.1. Country Segmental Analysis
- 17.8.2. Offering
- 17.8.3. Technological
- 17.8.4. Drug Type
- 17.8.5. Discovery Stage
- 17.8.6. Therapeutic Area
- 17.8.7. Deployment Mode
- 17.8.8. Data Type
- 17.8.9. Application
- 17.8.10. End User
- 17.9. Netherlands AI-Powered Drug Discovery Market
- 17.9.1. Country Segmental Analysis
- 17.9.2. Offering
- 17.9.3. Technological
- 17.9.4. Drug Type
- 17.9.5. Discovery Stage
- 17.9.6. Therapeutic Area
- 17.9.7. Deployment Mode
- 17.9.8. Data Type
- 17.9.9. Application
- 17.9.10. End User
- 17.10. Nordic Countries AI-Powered Drug Discovery Market
- 17.10.1. Country Segmental Analysis
- 17.10.2. Offering
- 17.10.3. Technological
- 17.10.4. Drug Type
- 17.10.5. Discovery Stage
- 17.10.6. Therapeutic Area
- 17.10.7. Deployment Mode
- 17.10.8. Data Type
- 17.10.9. Application
- 17.10.10. End User
- 17.11. Poland AI-Powered Drug Discovery Market
- 17.11.1. Country Segmental Analysis
- 17.11.2. Offering
- 17.11.3. Technological
- 17.11.4. Drug Type
- 17.11.5. Discovery Stage
- 17.11.6. Therapeutic Area
- 17.11.7. Deployment Mode
- 17.11.8. Data Type
- 17.11.9. Application
- 17.11.10. End User
- 17.12. Russia & CIS AI-Powered Drug Discovery Market
- 17.12.1. Country Segmental Analysis
- 17.12.2. Offering
- 17.12.3. Technological
- 17.12.4. Drug Type
- 17.12.5. Discovery Stage
- 17.12.6. Therapeutic Area
- 17.12.7. Deployment Mode
- 17.12.8. Data Type
- 17.12.9. Application
- 17.12.10. End User
- 17.13. Rest of Europe AI-Powered Drug Discovery Market
- 17.13.1. Country Segmental Analysis
- 17.13.2. Offering
- 17.13.3. Technological
- 17.13.4. Drug Type
- 17.13.5. Discovery Stage
- 17.13.6. Therapeutic Area
- 17.13.7. Deployment Mode
- 17.13.8. Data Type
- 17.13.9. Application
- 17.13.10. End User
- 18. Asia Pacific AI-Powered Drug Discovery Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. Asia Pacific AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 18.3.1. Offering
- 18.3.2. Technological
- 18.3.3. Drug Type
- 18.3.4. Discovery Stage
- 18.3.5. Therapeutic Area
- 18.3.6. Deployment Mode
- 18.3.7. Data Type
- 18.3.8. Application
- 18.3.9. End User
- 18.3.10. Country
- 18.3.10.1. China
- 18.3.10.2. India
- 18.3.10.3. Japan
- 18.3.10.4. South Korea
- 18.3.10.5. Australia and New Zealand
- 18.3.10.6. Indonesia
- 18.3.10.7. Malaysia
- 18.3.10.8. Thailand
- 18.3.10.9. Vietnam
- 18.3.10.10. Rest of Asia Pacific
- 18.4. China AI-Powered Drug Discovery Market
- 18.4.1. Country Segmental Analysis
- 18.4.2. Offering
- 18.4.3. Technological
- 18.4.4. Drug Type
- 18.4.5. Discovery Stage
- 18.4.6. Therapeutic Area
- 18.4.7. Deployment Mode
- 18.4.8. Data Type
- 18.4.9. Application
- 18.4.10. End User
- 18.5. India AI-Powered Drug Discovery Market
- 18.5.1. Country Segmental Analysis
- 18.5.2. Offering
- 18.5.3. Technological
- 18.5.4. Drug Type
- 18.5.5. Discovery Stage
- 18.5.6. Therapeutic Area
- 18.5.7. Deployment Mode
- 18.5.8. Data Type
- 18.5.9. Application
- 18.5.10. End User
- 18.6. Japan AI-Powered Drug Discovery Market
- 18.6.1. Country Segmental Analysis
- 18.6.2. Offering
- 18.6.3. Technological
- 18.6.4. Drug Type
- 18.6.5. Discovery Stage
- 18.6.6. Therapeutic Area
- 18.6.7. Deployment Mode
- 18.6.8. Data Type
- 18.6.9. Application
- 18.6.10. End User
- 18.7. South Korea AI-Powered Drug Discovery Market
- 18.7.1. Country Segmental Analysis
- 18.7.2. Offering
- 18.7.3. Technological
- 18.7.4. Drug Type
- 18.7.5. Discovery Stage
- 18.7.6. Therapeutic Area
- 18.7.7. Deployment Mode
- 18.7.8. Data Type
- 18.7.9. Application
- 18.7.10. End User
- 18.8. Australia and New Zealand AI-Powered Drug Discovery Market
- 18.8.1. Country Segmental Analysis
- 18.8.2. Offering
- 18.8.3. Technological
- 18.8.4. Drug Type
- 18.8.5. Discovery Stage
- 18.8.6. Therapeutic Area
- 18.8.7. Deployment Mode
- 18.8.8. Data Type
- 18.8.9. Application
- 18.8.10. End User
- 18.9. Indonesia AI-Powered Drug Discovery Market
- 18.9.1. Country Segmental Analysis
- 18.9.2. Offering
- 18.9.3. Technological
- 18.9.4. Drug Type
- 18.9.5. Discovery Stage
- 18.9.6. Therapeutic Area
- 18.9.7. Deployment Mode
- 18.9.8. Data Type
- 18.9.9. Application
- 18.9.10. End User
- 18.10. Malaysia AI-Powered Drug Discovery Market
- 18.10.1. Country Segmental Analysis
- 18.10.2. Offering
- 18.10.3. Technological
- 18.10.4. Drug Type
- 18.10.5. Discovery Stage
- 18.10.6. Therapeutic Area
- 18.10.7. Deployment Mode
- 18.10.8. Data Type
- 18.10.9. Application
- 18.10.10. End User
- 18.11. Thailand AI-Powered Drug Discovery Market
- 18.11.1. Country Segmental Analysis
- 18.11.2. Offering
- 18.11.3. Technological
- 18.11.4. Drug Type
- 18.11.5. Discovery Stage
- 18.11.6. Therapeutic Area
- 18.11.7. Deployment Mode
- 18.11.8. Data Type
- 18.11.9. Application
- 18.11.10. End User
- 18.12. Vietnam AI-Powered Drug Discovery Market
- 18.12.1. Country Segmental Analysis
- 18.12.2. Offering
- 18.12.3. Technological
- 18.12.4. Drug Type
- 18.12.5. Discovery Stage
- 18.12.6. Therapeutic Area
- 18.12.7. Deployment Mode
- 18.12.8. Data Type
- 18.12.9. Application
- 18.12.10. End User
- 18.13. Rest of Asia Pacific AI-Powered Drug Discovery Market
- 18.13.1. Country Segmental Analysis
- 18.13.2. Offering
- 18.13.3. Technological
- 18.13.4. Drug Type
- 18.13.5. Discovery Stage
- 18.13.6. Therapeutic Area
- 18.13.7. Deployment Mode
- 18.13.8. Data Type
- 18.13.9. Application
- 18.13.10. End User
- 19. Middle East AI-Powered Drug Discovery Market Analysis
- 19.1. Key Segment Analysis
- 19.2. Regional Snapshot
- 19.3. Middle East AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 19.3.1. Offering
- 19.3.2. Technological
- 19.3.3. Drug Type
- 19.3.4. Discovery Stage
- 19.3.5. Therapeutic Area
- 19.3.6. Deployment Mode
- 19.3.7. Data Type
- 19.3.8. Application
- 19.3.9. End User
- 19.3.10. Country
- 19.3.10.1. Turkey
- 19.3.10.2. UAE
- 19.3.10.3. Saudi Arabia
- 19.3.10.4. Israel
- 19.3.10.5. Rest of Middle East
- 19.4. Turkey AI-Powered Drug Discovery Market
- 19.4.1. Country Segmental Analysis
- 19.4.2. Offering
- 19.4.3. Technological
- 19.4.4. Drug Type
- 19.4.5. Discovery Stage
- 19.4.6. Therapeutic Area
- 19.4.7. Deployment Mode
- 19.4.8. Data Type
- 19.4.9. Application
- 19.4.10. End User
- 19.5. UAE AI-Powered Drug Discovery Market
- 19.5.1. Country Segmental Analysis
- 19.5.2. Offering
- 19.5.3. Technological
- 19.5.4. Drug Type
- 19.5.5. Discovery Stage
- 19.5.6. Therapeutic Area
- 19.5.7. Deployment Mode
- 19.5.8. Data Type
- 19.5.9. Application
- 19.5.10. End User
- 19.6. Saudi Arabia AI-Powered Drug Discovery Market
- 19.6.1. Country Segmental Analysis
- 19.6.2. Offering
- 19.6.3. Technological
- 19.6.4. Drug Type
- 19.6.5. Discovery Stage
- 19.6.6. Therapeutic Area
- 19.6.7. Deployment Mode
- 19.6.8. Data Type
- 19.6.9. Application
- 19.6.10. End User
- 19.7. Israel AI-Powered Drug Discovery Market
- 19.7.1. Country Segmental Analysis
- 19.7.2. Offering
- 19.7.3. Technological
- 19.7.4. Drug Type
- 19.7.5. Discovery Stage
- 19.7.6. Therapeutic Area
- 19.7.7. Deployment Mode
- 19.7.8. Data Type
- 19.7.9. Application
- 19.7.10. End User
- 19.8. Rest of Middle East AI-Powered Drug Discovery Market
- 19.8.1. Country Segmental Analysis
- 19.8.2. Offering
- 19.8.3. Technological
- 19.8.4. Drug Type
- 19.8.5. Discovery Stage
- 19.8.6. Therapeutic Area
- 19.8.7. Deployment Mode
- 19.8.8. Data Type
- 19.8.9. Application
- 19.8.10. End User
- 20. Africa AI-Powered Drug Discovery Market Analysis
- 20.1. Key Segment Analysis
- 20.2. Regional Snapshot
- 20.3. Africa AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 20.3.1. Offering
- 20.3.2. Technological
- 20.3.3. Drug Type
- 20.3.4. Discovery Stage
- 20.3.5. Therapeutic Area
- 20.3.6. Deployment Mode
- 20.3.7. Data Type
- 20.3.8. Application
- 20.3.9. End User
- 20.3.10. Country
- 20.3.10.1. South Africa
- 20.3.10.2. Egypt
- 20.3.10.3. Nigeria
- 20.3.10.4. Algeria
- 20.3.10.5. Rest of Africa
- 20.4. South Africa AI-Powered Drug Discovery Market
- 20.4.1. Country Segmental Analysis
- 20.4.2. Offering
- 20.4.3. Technological
- 20.4.4. Drug Type
- 20.4.5. Discovery Stage
- 20.4.6. Therapeutic Area
- 20.4.7. Deployment Mode
- 20.4.8. Data Type
- 20.4.9. Application
- 20.4.10. End User
- 20.5. Egypt AI-Powered Drug Discovery Market
- 20.5.1. Country Segmental Analysis
- 20.5.2. Offering
- 20.5.3. Technological
- 20.5.4. Drug Type
- 20.5.5. Discovery Stage
- 20.5.6. Therapeutic Area
- 20.5.7. Deployment Mode
- 20.5.8. Data Type
- 20.5.9. Application
- 20.5.10. End User
- 20.6. Nigeria AI-Powered Drug Discovery Market
- 20.6.1. Country Segmental Analysis
- 20.6.2. Offering
- 20.6.3. Technological
- 20.6.4. Drug Type
- 20.6.5. Discovery Stage
- 20.6.6. Therapeutic Area
- 20.6.7. Deployment Mode
- 20.6.8. Data Type
- 20.6.9. Application
- 20.6.10. End User
- 20.7. Algeria AI-Powered Drug Discovery Market
- 20.7.1. Country Segmental Analysis
- 20.7.2. Offering
- 20.7.3. Technological
- 20.7.4. Drug Type
- 20.7.5. Discovery Stage
- 20.7.6. Therapeutic Area
- 20.7.7. Deployment Mode
- 20.7.8. Data Type
- 20.7.9. Application
- 20.7.10. End User
- 20.8. Rest of Africa AI-Powered Drug Discovery Market
- 20.8.1. Country Segmental Analysis
- 20.8.2. Offering
- 20.8.3. Technological
- 20.8.4. Drug Type
- 20.8.5. Discovery Stage
- 20.8.6. Therapeutic Area
- 20.8.7. Deployment Mode
- 20.8.8. Data Type
- 20.8.9. Application
- 20.8.10. End User
- 21. South America AI-Powered Drug Discovery Market Analysis
- 21.1. Key Segment Analysis
- 21.2. Regional Snapshot
- 21.3. South America AI-Powered Drug Discovery Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
- 21.3.1. Offering
- 21.3.2. Technological
- 21.3.3. Drug Type
- 21.3.4. Discovery Stage
- 21.3.5. Therapeutic Area
- 21.3.6. Deployment Mode
- 21.3.7. Data Type
- 21.3.8. Application
- 21.3.9. End User
- 21.3.10. Country
- 21.3.10.1. Brazil
- 21.3.10.2. Argentina
- 21.3.10.3. Rest of South America
- 21.4. Brazil AI-Powered Drug Discovery Market
- 21.4.1. Country Segmental Analysis
- 21.4.2. Offering
- 21.4.3. Technological
- 21.4.4. Drug Type
- 21.4.5. Discovery Stage
- 21.4.6. Therapeutic Area
- 21.4.7. Deployment Mode
- 21.4.8. Data Type
- 21.4.9. Application
- 21.4.10. End User
- 21.5. Argentina AI-Powered Drug Discovery Market
- 21.5.1. Country Segmental Analysis
- 21.5.2. Offering
- 21.5.3. Technological
- 21.5.4. Drug Type
- 21.5.5. Discovery Stage
- 21.5.6. Therapeutic Area
- 21.5.7. Deployment Mode
- 21.5.8. Data Type
- 21.5.9. Application
- 21.5.10. End User
- 21.6. Rest of South America AI-Powered Drug Discovery Market
- 21.6.1. Country Segmental Analysis
- 21.6.2. Offering
- 21.6.3. Technological
- 21.6.4. Offering
- 21.6.5. Discovery Stage
- 21.6.6. Crop Type
- 21.6.7. Deployment Mode
- 21.6.8. Data Type
- 21.6.9. End User
- 22. Key Players/ Company Profile
- 22.1. Atomwise, Inc.
- 22.1.1. Company Details/ Overview
- 22.1.2. Company Financials
- 22.1.3. Key Customers and Competitors
- 22.1.4. Business/ Industry Portfolio
- 22.1.5. Product Portfolio/ Specification Details
- 22.1.6. Pricing Data
- 22.1.7. Strategic Overview
- 22.1.8. Recent Developments
- 22.2. BenevolentAI Limited
- 22.3. Berg LLC
- 22.4. BioXcel Therapeutics, Inc.
- 22.5. Cyclica Inc.
- 22.6. Deep Genomics Inc.
- 22.7. Exscientia plc
- 22.8. Healx Limited
- 22.9. Iktos S.A.
- 22.10. Insilico Medicine, Inc.
- 22.11. Insitro, Inc.
- 22.12. Lantern Pharma Inc.
- 22.13. Numerate, Inc.
- 22.14. Owkin, Inc.
- 22.15. Recursion Pharmaceuticals, Inc.
- 22.16. Schrödinger, Inc.
- 22.17. Standigm Inc.
- 22.18. Valo Health, Inc.
- 22.19. Verge Genomics, Inc.
- 22.20. XtalPi Inc.
- 22.21. Other Key Players
- 22.1. Atomwise, Inc.
Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography
Research Design
Our research design integrates both demand-side and supply-side analysis through a balanced combination of primary and secondary research methodologies. By utilizing both bottom-up and top-down approaches alongside rigorous data triangulation methods, we deliver robust market intelligence that supports strategic decision-making.
MarketGenics' comprehensive research design framework ensures the delivery of accurate, reliable, and actionable market intelligence. Through the integration of multiple research approaches, rigorous validation processes, and expert analysis, we provide our clients with the insights needed to make informed strategic decisions and capitalize on market opportunities.
MarketGenics leverages a dedicated industry panel of experts and a comprehensive suite of paid databases to effectively collect, consolidate, and analyze market intelligence.
Our approach has consistently proven to be reliable and effective in generating accurate market insights, identifying key industry trends, and uncovering emerging business opportunities.
Through both primary and secondary research, we capture and analyze critical company-level data such as manufacturing footprints, including technical centers, R&D facilities, sales offices, and headquarters.
Our expert panel further enhances our ability to estimate market size for specific brands based on validated field-level intelligence.
Our data mining techniques incorporate both parametric and non-parametric methods, allowing for structured data collection, sorting, processing, and cleaning.
Demand projections are derived from large-scale data sets analyzed through proprietary algorithms, culminating in robust and reliable market sizing.
Research Approach
The bottom-up approach builds market estimates by starting with the smallest addressable market units and systematically aggregating them to create comprehensive market size projections.
This method begins with specific, granular data points and builds upward to create the complete market landscape.
Customer Analysis → Segmental Analysis → Geographical Analysis
The top-down approach starts with the broadest possible market data and systematically narrows it down through a series of filters and assumptions to arrive at specific market segments or opportunities.
This method begins with the big picture and works downward to increasingly specific market slices.
TAM → SAM → SOM
Research Methods
Desk / Secondary Research
While analysing the market, we extensively study secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and commercial report. Secondary sources that we utilize are not only the public sources, but it is a combination of Open Source, Associations, Paid Databases, MG Repository & Knowledgebase, and others.
- Company websites, annual reports, financial reports, broker reports, and investor presentations
- National government documents, statistical databases and reports
- News articles, press releases and web-casts specific to the companies operating in the market, Magazines, reports, and others
- We gather information from commercial data sources for deriving company specific data such as segmental revenue, share for geography, product revenue, and others
- Internal and external proprietary databases (industry-specific), relevant patent, and regulatory databases
- Governing Bodies, Government Organizations
- Relevant Authorities, Country-specific Associations for Industries
We also employ the model mapping approach to estimate the product level market data through the players' product portfolio
Primary Research
Primary research/ interviews is vital in analyzing the market. Most of the cases involves paid primary interviews. Primary sources include primary interviews through e-mail interactions, telephonic interviews, surveys as well as face-to-face interviews with the different stakeholders across the value chain including several industry experts.
| Type of Respondents | Number of Primaries |
|---|---|
| Tier 2/3 Suppliers | ~20 |
| Tier 1 Suppliers | ~25 |
| End-users | ~25 |
| Industry Expert/ Panel/ Consultant | ~30 |
| Total | ~100 |
MG Knowledgebase
• Repository of industry blog, newsletter and case studies
• Online platform covering detailed market reports, and company profiles
Forecasting Factors and Models
Forecasting Factors
- Historical Trends – Past market patterns, cycles, and major events that shaped how markets behave over time. Understanding past trends helps predict future behavior.
- Industry Factors – Specific characteristics of the industry like structure, regulations, and innovation cycles that affect market dynamics.
- Macroeconomic Factors – Economic conditions like GDP growth, inflation, and employment rates that affect how much money people have to spend.
- Demographic Factors – Population characteristics like age, income, and location that determine who can buy your product.
- Technology Factors – How quickly people adopt new technology and how much technology infrastructure exists.
- Regulatory Factors – Government rules, laws, and policies that can help or restrict market growth.
- Competitive Factors – Analyzing competition structure such as degree of competition and bargaining power of buyers and suppliers.
Forecasting Models / Techniques
Multiple Regression Analysis
- Identify and quantify factors that drive market changes
- Statistical modeling to establish relationships between market drivers and outcomes
Time Series Analysis – Seasonal Patterns
- Understand regular cyclical patterns in market demand
- Advanced statistical techniques to separate trend, seasonal, and irregular components
Time Series Analysis – Trend Analysis
- Identify underlying market growth patterns and momentum
- Statistical analysis of historical data to project future trends
Expert Opinion – Expert Interviews
- Gather deep industry insights and contextual understanding
- In-depth interviews with key industry stakeholders
Multi-Scenario Development
- Prepare for uncertainty by modeling different possible futures
- Creating optimistic, pessimistic, and most likely scenarios
Time Series Analysis – Moving Averages
- Sophisticated forecasting for complex time series data
- Auto-regressive integrated moving average models with seasonal components
Econometric Models
- Apply economic theory to market forecasting
- Sophisticated economic models that account for market interactions
Expert Opinion – Delphi Method
- Harness collective wisdom of industry experts
- Structured, multi-round expert consultation process
Monte Carlo Simulation
- Quantify uncertainty and probability distributions
- Thousands of simulations with varying input parameters
Research Analysis
Our research framework is built upon the fundamental principle of validating market intelligence from both demand and supply perspectives. This dual-sided approach ensures comprehensive market understanding and reduces the risk of single-source bias.
Demand-Side Analysis: We understand end-user/application behavior, preferences, and market needs along with the penetration of the product for specific application.
Supply-Side Analysis: We estimate overall market revenue, analyze the segmental share along with industry capacity, competitive landscape, and market structure.
Validation & Evaluation
Data triangulation is a validation technique that uses multiple methods, sources, or perspectives to examine the same research question, thereby increasing the credibility and reliability of research findings. In market research, triangulation serves as a quality assurance mechanism that helps identify and minimize bias, validate assumptions, and ensure accuracy in market estimates.
- Data Source Triangulation – Using multiple data sources to examine the same phenomenon
- Methodological Triangulation – Using multiple research methods to study the same research question
- Investigator Triangulation – Using multiple researchers or analysts to examine the same data
- Theoretical Triangulation – Using multiple theoretical perspectives to interpret the same data
Custom Market Research Services
We will customise the research for you, in case the report listed above does not meet your requirements.
Get 10% Free Customisation